CA
NZ
UK
AU
IND
US
Biogen (NASDAQ: BIIB) has faced a structural commercial challenge in neurology for several years. Multiple sclerosis revenues have been under pressure from generic and biosimilar competition, and the Alzheimer's programme, while scientifically groundbreaking, has generated more controversy than commercial clarity. Against that backdrop, the …
Moderna Inc. (NASDAQ: MRNA) is awaiting a pivotal recommendation from a federal vaccine advisory committee as regulators evaluate the safety and effectiveness of its experimental influenza vaccine for adults aged 50 and older. The review is being closely watched across the biotechnology sector because …
Kardigan made a strong debut on the public markets after the cardiovascular drug developer completed a $400 million upsized initial public offering, reflecting improving investor sentiment toward biotechnology listings.
Novocure Limited (NASDAQ:NVCR) fell 11.89% in June 18 pre-market trading to USD 15.73 after closing at USD 17.85 on June 17.
Novocure (NASDAQ:NVCR) announced results from the TRIDENT trial on June 18, 2026. The company wanted to answer a straightforward question: should patients with newly diagnosed glioblastoma begin Tumor Treating Fields therapy immediately alongside chemotherapy and radiation, or wait until the maintenance stage after chemoradiation …
Shares of Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 15.05% to $2.43 in premarket trading today, June 18, 2026, after the US Food and Drug Administration approved Utebzi for certain adults with complicated urinary tract infections.
uniQure (NASDAQ: QURE) shares climbed in premarket trading after the company disclosed a breakthrough outcome from a formal meeting with U.S. regulators over its Huntington's disease gene therapy programme. The FDA confirmed that long-term data from its ongoing clinical trial will be sufficient to …
Gossamer Bio (NASDAQ: GOSS) has executed the final settlement of a large-scale convertible debt exchange, successfully converting the overwhelming majority of its near-term note obligations into a restructured mix of longer-dated debt and equity. The transaction, which closed its final exchange window on June …
Elicio Therapeutics (NASDAQ: ELTX) shares fell in premarket trading after its AMPLIFY-7P Phase 2 trial failed its primary endpoint, even as complete responses emerged in a typically immunotherapy-resistant patient subgroup.Key HighlightsTrial failure: Elicio Therapeutics' AMPLIFY-7P Phase 2 trial did not meet its primary endpoint …
Ainos, Inc. (NASDAQ: AIMD) has formalised a 12-month research agreement with National Taiwan University to investigate whether its Smell AI breath-print analysis technology can be applied to triage patients presenting with acute breathing difficulties in emergency department settings. The collaboration begins in July 2026 …
Please wait processing your request...